Chemotherapy‐Mediated Induction of PD‐L1 via SEI1 Facilitates Myeloma Immune Evasion

Chemotherapy‐Mediated Induction of PD‐L1 via SEI1 Facilitates Myeloma Immune Evasion

Abstract Multiple myeloma (MM) is a plasma cell‐derived malignancy. While immune checkpoint blockade immunotherapy has advanced myeloma treatment, chemotherapy remains the primary therapy. How chemotherapy interacts with immune checkpoint expression and impacts immunotherapy efficacy remains unclear...

Full description

Saved in:

Bibliographic Details
Main Authors:	Rui Chen, Zongwei Li, Zhihong Fang, Zou Li, Daoyan Yang, Yuan Li, Shurong Liu, Zhiqiang Liu, Rui Liu, Huan Liu
Format:	Article
Language:	English
Published:	Wiley 2025-05-01
Series:	Advanced Science
Subjects:	chemotherapy immune evasion multiple myeloma PD‐L1 SEI1
Online Access:	https://doi.org/10.1002/advs.202411082
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis
by: Yi Huang, et al.
Published: (2024-12-01)

The PD-1/PD-L1 pathway and Epstein–Barr virus
by: Hui Wang, et al.
Published: (2025-06-01)

Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1
by: Suli Wang, et al.
Published: (2024-11-01)

Unexpected PD‐L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies
by: Tanmoy Mondal, et al.
Published: (2021-02-01)

NSUN2/ALYREF axis-driven m5C methylation enhances PD-L1 expression and facilitates immune evasion in non-small-cell lung cancer
by: Yiran Yang, et al.
Published: (2025-03-01)

Tumor-associated bacteria activate PRDX1-driven glycolysis to promote immune evasion and PD-1 antibody resistance in hepatocellular carcinoma
by: Heng Zhang, et al.
Published: (2025-07-01)

Claudin-9 (CLDN9) promotes gastric cancer progression by enhancing the glycolysis pathway and facilitating PD-L1 lactylation to suppress CD8+ T cell anti-tumor immunity
by: Xingbin Hu, et al.
Published: (2025-05-01)

Dendritic cells in multiple myeloma: from immune evasion to therapeutic potential
by: Melanie Andrea Jordan, et al.
Published: (2025-04-01)

Targeting Exosomal PD-L1 as a New Frontier in Cancer Immunotherapy
by: Laura Denisa Dragu, et al.
Published: (2025-07-01)

Gingipain regulates isoform switches of PD-L1 in macrophages infected with Porphyromonas gingivalis
by: Yilin Zheng, et al.
Published: (2025-03-01)

Enterohemorrhagic Escherichia coli Tir inhibits TAK1 activation and mediates immune evasion
by: Ruixue Zhou, et al.
Published: (2019-01-01)

Activity of Negative Regulation of the PD-1/PD-L1/PD-L2 T-Cell Response System in Patients with Pneumonia and Inﬂuenza A (H1N1)
by: A. V. Malyarchikov, et al.
Published: (2021-08-01)

PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution
by: Ryohei Kondo, et al.
Published: (2025-05-01)

The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer
by: Qian Zhu, et al.
Published: (2025-04-01)

Ginseng-Derived Exosomes Attenuate Immune Evasion in NSCLC via PD-L1 Modulation
by: Zhu LJ, et al.
Published: (2025-07-01)

A bibliometric analysis of research on PD-1/PD-L1 in urinary tract tumors
by: Yongming Chen, et al.
Published: (2024-12-01)

Evaluation of polymorphism in BCL-2, PD-1, and PD-L1 genes in myelodysplastic neoplasms
by: Bartłomiej Kuszczak, et al.
Published: (2025-01-01)

PD-1/PD-L1 and coronary heart disease: a mendelian randomization study
by: Liangjia Zeng, et al.
Published: (2024-10-01)

Development and validation of interpretable machine learning models for predicting AKI risk in patients treated with PD-1/PD-L1: a retrospective study
by: Wentong Liu, et al.
Published: (2025-08-01)

Impact of rheumatoid factors on the function of therapeutic monoclonals specific for PD-1/PD-L1
by: Barry D. Hock, et al.
Published: (2025-05-01)

Efficacy and safety of PD-1 and PD-L1 inhibitors in advanced colorectal cancer: a meta-analysis of randomized controlled trials
by: Zhenzi Wang, et al.
Published: (2024-12-01)

Inhibiting ADORA1 enhances glioma apoptosis and increases its sensitivity to anti-PD1 therapy
by: Hong-jiang Li, et al.
Published: (2025-05-01)

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
by: Qichen Zhang, et al.
Published: (2025-01-01)

Current perspectives on tertiary lymphoid structures and PD-1/PD-L1 signaling pathway in the immunotherapy of hepatocellular carcinoma
by: Hao-Dong QIAO, et al.
Published: (2023-10-01)

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
by: Yizhou Zhang, et al.
Published: (2024-12-01)

Visualization of PD-L1-positive and PD-1-positive immune cell contact in the breast cancer microenvironment
by: A. Yu. Kalinchuk, et al.
Published: (2024-03-01)

The efficacy and safety of regorafenib/fruquintinib combined with PD-1/PD-L1 for metastatic colorectal cancer: a meta-analysis based on single-arm studies
by: Fan Yang, et al.
Published: (2025-05-01)

Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends
by: Talaiti Tuergan, et al.
Published: (2025-12-01)

Efficacy and safety outcomes of PD-1/PD-L1 inhibitors in recurrent cholangiocarcinoma: a real-world, multicenter and retrospective study
by: Lihui Lin, et al.
Published: (2025-07-01)

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1
by: Mengzhen Jiang, et al.
Published: (2023-12-01)

The potential role of HPV oncoproteins in the PD-L1/PD-1 pathway in cervical cancer: new perspectives on cervical cancer immunotherapy
by: Jin Li, et al.
Published: (2024-12-01)

Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer
by: Hongshu Li, et al.
Published: (2025-04-01)

Advances in PD-1/PD-L1 pathway inhibitors in the treatment of thyroid cancer: mechanisms and clinical therapeutic perspectives
by: Xizi Li, et al.
Published: (2025-08-01)

The regulatory effects of PD-1/PD-L1 inhibitors on bone metabolism: opportunities and challenges in osteoporosis management
by: Jia-Wen Wang, et al.
Published: (2025-07-01)

The current status and prospects of gut microbiota combined with PD-1/PD-L1 inhibitors in the treatment of colorectal cancer: a review
by: Min Deng, et al.
Published: (2025-05-01)

Mesenchymal stem cell-derived extracellular vesicles alleviate autism by regulating microglial glucose metabolism reprogramming and neuroinflammation through PD-1/PD-L1 interaction
by: Qian Qin, et al.
Published: (2025-03-01)

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
by: Miren Zuazo, et al.
Published: (2019-06-01)

CircNF1 modulates the progression and immune evasion of esophageal squamous cell carcinoma through dual regulation of PD-L1
by: Chang Wang, et al.
Published: (2025-03-01)

Integrating clinical trial landscapes and bibliometric analysis: unveiling the impact of PD-1/PD-L1 inhibitors on renal cell carcinoma research and therapeutic trajectories summary
by: Yuanbin Huang, et al.
Published: (2025-07-01)

Thyroid dysfunction as a predictor of PD- 1/PD-L1 inhibitor efficacy in advanced lung cancer
by: Yanling Wang, et al.
Published: (2025-04-01)